Tengji Biomedical Technology

Tengji Biomedical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the development of next-generation gene therapies. The company was founded by Dr. Wei-Dong Xiao, a globally recognized expert in adeno-associated virus (AAV) research, to address unmet medical needs in rare genetic diseases. Tengji utilizes a proprietary AAV vector platform to design and manufacture high-potency gene delivery vehicles. Its lead candidate, TG-001, is currently in clinical development for the treatment of Hemophilia B. Beyond hematology, the company is expanding its pipeline into metabolic and neuromuscular disorders, including Pompe disease. The company maintains integrated capabilities spanning from early-stage discovery to GMP-compliant manufacturing.